The FDA reversed an earlier refusal and agreed to review Moderna’s mRNA seasonal influenza vaccine mRNA‑1010 after a Type A meeting, assigning a target action date of Aug. 5. The agency will assess traditional approval for adults 50–64 and accelerated approval for those 65+, with a required post‑marketing study in older adults. Moderna said it amended its submission to address the regulator’s concerns about trial comparators. The unusual back‑and‑forth highlighted internal agency tensions over trial design and reviewer discretion and underscored broader scrutiny of mRNA vaccine dossiers under current leadership.